Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.

Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Espejo C, Álvarez-Cermeño JC, Villar LM, Guaza C.

Front Immunol. 2019 Jun 14;10:1374. doi: 10.3389/fimmu.2019.01374. eCollection 2019.

2.

The endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia.

Mecha M, Yanguas-Casás N, Feliú A, Mestre L, Carrillo-Salinas F, Azcoitia I, Yong VW, Guaza C.

Brain Behav Immun. 2019 Mar;77:110-126. doi: 10.1016/j.bbi.2018.12.013. Epub 2018 Dec 21.

3.

Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis.

Laso-García F, Ramos-Cejudo J, Carrillo-Salinas FJ, Otero-Ortega L, Feliú A, Gómez-de Frutos M, Mecha M, Díez-Tejedor E, Guaza C, Gutiérrez-Fernández M.

PLoS One. 2018 Sep 19;13(9):e0202590. doi: 10.1371/journal.pone.0202590. eCollection 2018.

4.

Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis.

Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Guaza C.

Biochem Pharmacol. 2018 Nov;157:51-66. doi: 10.1016/j.bcp.2018.08.037. Epub 2018 Aug 30. Review.

PMID:
30171835
5.

Development of a Fluorescent Bodipy Probe for Visualization of the Serotonin 5-HT1A Receptor in Native Cells of the Immune System.

Hernández-Torres G, Enríquez-Palacios E, Mecha M, Feliú A, Rueda-Zubiaurre A, Angelina A, Martín-Cruz L, Martín-Fontecha M, Palomares O, Guaza C, Peña-Cabrera E, López-Rodríguez ML, Ortega-Gutiérrez S.

Bioconjug Chem. 2018 Jun 20;29(6):2021-2027. doi: 10.1021/acs.bioconjchem.8b00228. Epub 2018 May 14.

PMID:
29733594
6.

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.

Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Muñoz E.

J Neuroinflammation. 2018 Mar 1;15(1):64. doi: 10.1186/s12974-018-1103-y.

7.

2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs.

Mecha M, Feliú A, Machín I, Cordero C, Carrillo-Salinas F, Mestre L, Hernández-Torres G, Ortega-Gutiérrez S, López-Rodríguez ML, de Castro F, Clemente D, Guaza C.

Glia. 2018 Jul;66(7):1447-1463. doi: 10.1002/glia.23317. Epub 2018 Feb 27.

PMID:
29484707
8.

2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Feliú A, Bonilla Del Río I, Carrillo-Salinas FJ, Hernández-Torres G, Mestre L, Puente N, Ortega-Gutiérrez S, López-Rodríguez ML, Grandes P, Mecha M, Guaza C.

J Neurosci. 2017 Aug 30;37(35):8385-8398. doi: 10.1523/JNEUROSCI.2900-16.2017. Epub 2017 Jul 27.

9.

Should We Stop Saying 'Glia' and 'Neuroinflammation'?

Masgrau R, Guaza C, Ransohoff RM, Galea E.

Trends Mol Med. 2017 Jun;23(6):486-500. doi: 10.1016/j.molmed.2017.04.005. Epub 2017 May 9. Review.

PMID:
28499701
10.

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus.

Carrillo-Salinas FJ, Mestre L, Mecha M, Feliú A, Del Campo R, Villarrubia N, Espejo C, Montalbán X, Álvarez-Cermeño JC, Villar LM, Guaza C.

Sci Rep. 2017 Mar 14;7:44377. doi: 10.1038/srep44377.

11.

Cannabinoid Receptors Modulate Neuronal Morphology and AnkyrinG Density at the Axon Initial Segment.

Tapia M, Dominguez A, Zhang W, Del Puerto A, Ciorraga M, Benitez MJ, Guaza C, Garrido JJ.

Front Cell Neurosci. 2017 Jan 25;11:5. doi: 10.3389/fncel.2017.00005. eCollection 2017.

12.

Correction: Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.

Lopez de Lapuente A, Feliú A, Ugidos N, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas FJ, Comabella M, Montalban X, Alloza I, Guaza C, Vandenbroeck K.

J Immunol. 2016 Nov 15;197(10):4177. No abstract available.

13.

Microglia activation states and cannabinoid system: Therapeutic implications.

Mecha M, Carrillo-Salinas FJ, Feliú A, Mestre L, Guaza C.

Pharmacol Ther. 2016 Oct;166:40-55. doi: 10.1016/j.pharmthera.2016.06.011. Epub 2016 Jun 29. Review.

PMID:
27373505
14.

Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N.

J Med Chem. 2016 Jul 28;59(14):6753-6771. doi: 10.1021/acs.jmedchem.6b00397. Epub 2016 Jul 6.

15.

Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.

Lopez de Lapuente A, Feliú A, Ugidos N, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas FJ, Comabella M, Montalban X, Alloza I, Guaza C, Vandenbroeck K.

J Immunol. 2016 Jun 1;196(11):4553-65. doi: 10.4049/jimmunol.1501205. Epub 2016 May 4. Erratum in: J Immunol. 2016 Nov 15;197(10 ):4177.

16.

CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model.

Hernangómez M, Klusáková I, Joukal M, Hradilová-Svíženská I, Guaza C, Dubový P.

J Neuroinflammation. 2016 Feb 18;13:43. doi: 10.1186/s12974-016-0508-8.

17.

Brain-borne IL-1 adjusts glucoregulation and provides fuel support to astrocytes and neurons in an autocrine/paracrine manner.

Del Rey A, Verdenhalven M, Lörwald AC, Meyer C, Hernangómez M, Randolf A, Roggero E, König AM, Heverhagen JT, Guaza C, Besedovsky HO.

Mol Psychiatry. 2016 Sep;21(9):1309-20. doi: 10.1038/mp.2015.174. Epub 2015 Dec 8.

PMID:
26643538
18.

The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.

Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E.

Mult Scler Relat Disord. 2015 Nov;4(6):505-11. doi: 10.1016/j.msard.2015.08.001. Epub 2015 Aug 5.

PMID:
26590655
19.

Endocannabinoids drive the acquisition of an alternative phenotype in microglia.

Mecha M, Feliú A, Carrillo-Salinas FJ, Rueda-Zubiaurre A, Ortega-Gutiérrez S, de Sola RG, Guaza C.

Brain Behav Immun. 2015 Oct;49:233-45. doi: 10.1016/j.bbi.2015.06.002. Epub 2015 Jun 15.

PMID:
26086345
20.

PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Mestre L, Redondo M, Carrillo-Salinas FJ, Morales-García JA, Alonso-Gil S, Pérez-Castillo A, Gil C, Martínez A, Guaza C.

Br J Pharmacol. 2015 Sep;172(17):4277-90. doi: 10.1111/bph.13192. Epub 2015 Jul 14.

21.

A Basal Tone of 2-Arachidonoylglycerol Contributes to Early Oligodendrocyte Progenitor Proliferation by Activating Phosphatidylinositol 3-Kinase (PI3K)/AKT and the Mammalian Target of Rapamycin (MTOR) Pathways.

Gomez O, Sanchez-Rodriguez MA, Ortega-Gutierrez S, Vazquez-Villa H, Guaza C, Molina-Holgado F, Molina-Holgado E.

J Neuroimmune Pharmacol. 2015 Jun;10(2):309-17. doi: 10.1007/s11481-015-9609-x. Epub 2015 Apr 22.

PMID:
25900077
22.

A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.

Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C.

Br J Pharmacol. 2015 Jul;172(14):3579-95. doi: 10.1111/bph.13159. Epub 2015 May 20.

23.

A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis.

Hernández-Torres G, Cipriano M, Hedén E, Björklund E, Canales Á, Zian D, Feliú A, Mecha M, Guaza C, Fowler CJ, Ortega-Gutiérrez S, López-Rodríguez ML.

Angew Chem Int Ed Engl. 2014 Dec 8;53(50):13765-70. doi: 10.1002/anie.201407807. Epub 2014 Oct 8.

PMID:
25298214
24.

Regulatory lymphocytes are key factors in MHC-independent resistance to EAE.

Marín N, Mecha M, Espejo C, Mestre L, Eixarch H, Montalban X, Álvarez-Cermeño JC, Guaza C, Villar LM.

J Immunol Res. 2014;2014:156380. doi: 10.1155/2014/156380. Epub 2014 Apr 27.

25.

A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis.

Carrillo-Salinas FJ, Navarrete C, Mecha M, Feliú A, Collado JA, Cantarero I, Bellido ML, Muñoz E, Guaza C.

PLoS One. 2014 Apr 11;9(4):e94733. doi: 10.1371/journal.pone.0094733. eCollection 2014.

26.

Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system.

Hernangómez M, Carrillo-Salinas FJ, Mecha M, Correa F, Mestre L, Loría F, Feliú A, Docagne F, Guaza C.

Curr Pharm Des. 2014;20(29):4707-22. Review.

27.

Anti-myelin antibodies play an important role in the susceptibility to develop proteolipid protein-induced experimental autoimmune encephalomyelitis.

Marín N, Eixarch H, Mansilla MJ, Rodríguez-Martín E, Mecha M, Guaza C, Álvarez-Cermeño JC, Montalban X, Villar LM, Espejo C.

Clin Exp Immunol. 2014 Feb;175(2):202-7. doi: 10.1111/cei.12233.

28.

Mobilization of progenitors in the subventricular zone to undergo oligodendrogenesis in the Theiler's virus model of multiple sclerosis: implications for remyelination at lesions sites.

Mecha M, Feliú A, Carrillo-Salinas FJ, Mestre L, Guaza C.

Exp Neurol. 2013 Dec;250:348-52. doi: 10.1016/j.expneurol.2013.10.011. Epub 2013 Oct 19.

29.

The role of inflammatory mediators in immune-to-brain communication during health and disease.

Gomez-Nicola D, Teeling J, Guaza C, Godbout JP, Taub DD.

Mediators Inflamm. 2013;2013:429231. doi: 10.1155/2013/429231. Epub 2013 Sep 10. No abstract available.

30.

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.

Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C.

Neurobiol Dis. 2013 Nov;59:141-50. doi: 10.1016/j.nbd.2013.06.016. Epub 2013 Jul 11.

31.

Understanding microglia-neuron cross talk: relevance of the microglia-neuron cocultures.

Correa FG, Hernangómez M, Guaza C.

Methods Mol Biol. 2013;1041:215-29. doi: 10.1007/978-1-62703-520-0_20.

PMID:
23813382
32.

Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virus.

Mecha M, Carrillo-Salinas FJ, Mestre L, Feliú A, Guaza C.

Prog Neurobiol. 2013 Feb-Mar;101-102:46-64. doi: 10.1016/j.pneurobio.2012.11.003. Epub 2012 Nov 29.

PMID:
23201558
33.

A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.

Granja AG, Carrillo-Salinas F, Pagani A, Gómez-Cañas M, Negri R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Cantarero I, Calzado MA, Bellido ML, Fernandez-Ruiz J, Appendino G, Guaza C, Muñoz E.

J Neuroimmune Pharmacol. 2012 Dec;7(4):1002-16. doi: 10.1007/s11481-012-9399-3. Epub 2012 Sep 14.

PMID:
22971837
34.

Altered immune function in unaffected first-degree biological relatives of schizophrenia patients.

Martínez-Gras I, García-Sánchez F, Guaza C, Rodríguez-Jiménez R, Andrés-Esteban E, Palomo T, Rubio G, Borrell J.

Psychiatry Res. 2012 Dec 30;200(2-3):1022-5. doi: 10.1016/j.psychres.2012.05.036. Epub 2012 Jul 4.

PMID:
22766011
35.

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress.

Mecha M, Torrao AS, Mestre L, Carrillo-Salinas FJ, Mechoulam R, Guaza C.

Cell Death Dis. 2012 Jun 28;3:e331. doi: 10.1038/cddis.2012.71.

36.

Chemical probes for the recognition of cannabinoid receptors in native systems.

Martín-Couce L, Martín-Fontecha M, Palomares O, Mestre L, Cordomí A, Hernangomez M, Palma S, Pardo L, Guaza C, López-Rodríguez ML, Ortega-Gutiérrez S.

Angew Chem Int Ed Engl. 2012 Jul 9;51(28):6896-9. doi: 10.1002/anie.201200467. Epub 2012 Jun 11.

PMID:
22689411
37.

CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation.

Hernangómez M, Mestre L, Correa FG, Loría F, Mecha M, Iñigo PM, Docagne F, Williams RO, Borrell J, Guaza C.

Glia. 2012 Sep;60(9):1437-50. doi: 10.1002/glia.22366. Epub 2012 May 31.

PMID:
22653796
38.

A CB₁/CB₂ receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin.

Arevalo-Martin A, Molina-Holgado E, Guaza C.

Neuropharmacology. 2012 Sep;63(3):385-93. doi: 10.1016/j.neuropharm.2012.04.012. Epub 2012 Apr 27.

PMID:
22561283
39.

Cannabidiol-induced apoptosis in murine microglial cells through lipid raft.

Wu HY, Goble K, Mecha M, Wang CC, Huang CH, Guaza C, Jan TR.

Glia. 2012 Jul;60(7):1182-90. doi: 10.1002/glia.22345. Epub 2012 Apr 25.

PMID:
22535572
40.

[Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis].

Moreno B, Espejo C, Mestre L, Suardiaz M, Clemente D, de Castro F, Fernández-Fernández Ó, Montalban X, Villoslada P, Guaza C; Spanish Network for MS.

Rev Neurol. 2012 Jan 16;54(2):114-24. Spanish.

41.

Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases.

Moreno-Martet M, Mestre L, Loría F, Guaza C, Fernández-Ruiz J, de Lago E.

Neurosci Lett. 2012 Feb 6;508(2):67-72. doi: 10.1016/j.neulet.2011.12.020. Epub 2011 Dec 22.

PMID:
22206832
42.

Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology.

Fernandez AM, Jimenez S, Mecha M, Dávila D, Guaza C, Vitorica J, Torres-Aleman I.

Mol Psychiatry. 2012 Jul;17(7):705-18. doi: 10.1038/mp.2011.128. Epub 2011 Oct 18.

PMID:
22005929
43.

Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors.

Mestre L, Iñigo PM, Mecha M, Correa FG, Hernangómez-Herrero M, Loría F, Docagne F, Borrell J, Guaza C.

J Neuroinflammation. 2011 Aug 18;8:102. doi: 10.1186/1742-2094-8-102.

44.

Tissue plasminogen activator prevents white matter damage following stroke.

Correa F, Gauberti M, Parcq J, Macrez R, Hommet Y, Obiang P, Hernangómez M, Montagne A, Liot G, Guaza C, Maubert E, Ali C, Vivien D, Docagne F.

J Exp Med. 2011 Jun 6;208(6):1229-42. doi: 10.1084/jem.20101880. Epub 2011 May 16.

45.

Prospects for cannabinoid therapies in basal ganglia disorders.

Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Review.

46.

The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells.

Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, Guaza C.

Brain Behav Immun. 2011 May;25(4):736-49. doi: 10.1016/j.bbi.2011.01.020. Epub 2011 Feb 16.

PMID:
21310228
47.

Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout mice.

Gomez-Nicola D, Spagnolo A, Guaza C, Nieto-Sampedro M.

Exp Neurol. 2010 Apr;222(2):235-42. doi: 10.1016/j.expneurol.2009.12.034. Epub 2010 Jan 11.

PMID:
20070942
48.

An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.

Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C.

Neurobiol Dis. 2010 Jan;37(1):166-76. doi: 10.1016/j.nbd.2009.09.020. Epub 2009 Oct 6.

PMID:
19815071
49.

The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis.

Correa FG, Mestre L, Docagne F, Borrell J, Guaza C.

Vitam Horm. 2009;81:207-30. doi: 10.1016/S0083-6729(09)81009-1. Review.

PMID:
19647114
50.

Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB.

Correa F, Hernangómez M, Mestre L, Loría F, Spagnolo A, Docagne F, Di Marzo V, Guaza C.

Glia. 2010 Jan 15;58(2):135-47. doi: 10.1002/glia.20907.

PMID:
19565660

Supplemental Content

Support Center